Influenza H1N1 HA (A/California/04/2009) Recombinant Rabbit Monoclonal Antibody (10), Invitrogen™

Description

• This product is preservative free
• It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%)
• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• This antibody has specificity for H1N1 (A/California/04/2009) HA H1N1 (A/California/04/2009) HA1 Sub-unit H1N1 (A/California/07/2009) HA
• Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA
• In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States
• The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic
• Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins
• The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release
• These proteins also elicit immune responses that prevent infection or independently reduce viral replication
• The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin
• The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.